Summary
The United States District Court for the District of New Jersey granted Defendants’ motion to dismiss an amended securities class action complaint concerning public statements about patent litigation involving Pacira’s EXPAREL product. The court held that Plaintiff failed to plausibly plead actionable misrepresentations or omissions, materiality, and scienter under Section 10(b), Rule 10b-5, Rule 9(b), and the PSLRA. The derivative Section 20(a) claim was also dismissed, and the amended complaint was dismissed with prejudice.
Topics
Practice areas
Questions Presented
- Whether the amended complaint plausibly alleged actionable material misrepresentations or omissions under Section 10(b) of the Securities Exchange Act and SEC Rule 10b-5.
- Whether the alleged omission of the June 2023 claim-construction ruling was material.
- Whether the amended complaint pleaded scienter with the particularity required by the PSLRA.
- Whether the derivative Section 20(a) control-person claim could survive without a sufficiently pleaded primary Section 10(b) violation.
- Whether dismissal should be with prejudice and without leave to amend.
Holdings
- The amended complaint did not plausibly allege that Defendants’ challenged statements about Pacira’s patent litigation were false or misleading when made. The statements were non-actionable opinions, forward-looking assessments, or expressions of corporate optimism, and the alleged omission of the interim claim-construction ruling did not render the disclosures misleading.
- The amended complaint did not plausibly allege that omission of the June 2023 claim-construction ruling significantly altered the total mix of information available to investors.
- The amended complaint failed to plead a strong inference of scienter.
- The Section 20(a) claim failed because Plaintiff did not adequately plead the predicate Section 10(b) violation.
- Dismissal with prejudice and without leave to replead was appropriate because amendment would be futile.
Key quotations
“The issue before the Court on a Rule 12(b)(6) motion to dismiss “is not whether a plaintiff will ultimately prevail but whether the claimant is entitled to offer evidence to support the claims.”” (4)
“Securities laws do not require issuers like Defendants to characterize interim rulings or to concede defeat before a court has issued a ruling on the actual issue in the case.” (10)
“Because Plaintiff has not adequately pleaded a predicate Section 10(b) violation, the Court finds that the derivative Section 20(a) claim for control-person liability also fails as a matter of law.” (15)
Factual background
Pacira Biosciences marketed EXPAREL, its primary product, and held patents covering its formulations and manufacturing processes, including the ’495 Patent. After eVenus sought FDA approval to market a generic version, Pacira brought patent-infringement litigation, and a June 2023 claim-construction ruling rejected some of Pacira’s proposed interpretations. Plaintiff alleged that Pacira and its executives later made misleading statements about the strength and prospects of the patent litigation by failing to disclose the significance of that ruling. The patent was ultimately held invalid in August 2024, after which Pacira’s stock price declined substantially.
Procedural history
Plaintiff filed the original class-action complaint on January 13, 2025, and an amended complaint on July 21, 2025. Defendants moved to dismiss the amended complaint; after briefing, the district court granted the motion and dismissed the amended complaint with prejudice and without leave to replead because amendment would be futile.